Novavax’s COVID-19 vaccine enters Phase 1 trials – is Moderna in trouble?

A vaccine is an unlikely solution. However, biotechs often tirelessly work on vaccines even after the expiration date of a virus. For example, vaccines for ebola, Zika, and Sars2 are still in development. Thus if a vaccine is unattainable before COVID-19 fizzles out, biotechs will continue to create a vaccine. Because we do not want […]

Chinese company shows early signs of promising COVID-19 vaccine.

The vaccine race involves many runners, with the leaders being Moderna (NASDAQ: MRNA), Inovio (NASDAQ: INO), and Novavax (NASDAQ: NVAX). It feels like many vaccine companies are sprinting as they accelerate through the clinical timeline. However, the US government raised the stakes on Thursday when they announced a $1.2 billion injection into AstraZene’s untried vaccine. […]

Novavax look to repeat last week’s 120% gain.

Novavax (NASDAQ:NVAX) look to surge come market open with pre-market up 13% (at the time of writing). Novavax captured the wallets of investors last week when they received $384 million in vaccine funding from CEPI. This week NVAX is expected to captivate investors with a new all-time-high. Which seems achievable, especially if last week’s insane […]

Moderna set to surge after producing positive trial results for COVID-19 vaccine

Moderna announced this morning that their interim Phase 1 data for COVID-19 vaccine has shown positive results. The company has been heavily watched by investors and speculators alike – as their vaccine (mRNA-1273) continues to show positive signs. The announcement confirmed the Biomedical Advanced Research and Development Authority (BARDA) are in support of the companies phase […]

BREAKING: SRNE’s COVID-19 treatment offers 100% protection – is now the time to invest?

It seems most biotechs are reenacting the boy who cried wolf. Especially, as every week a new biotech enters the headlines for COVID-19 vaccine developments. In all honesty a single viable vaccine, let alone multiple, is unlikely. Testing and treatments is where is the consistent share price growth resides. Thus, when a COVID-19 treatment posts […]

Mesoblast set to surge off COVID-19 stem cell trials.

The world is in dire need of a COVID-19 treatment. A vaccine is the plan b for the long-term. However, governments can take action immediately through COVID-19 treatments and testing. Mesoblast (NASDAQ:MESO) and (ASX:MSB), an Australian biotech is developing a stem cell treatment (Remestemcel-L), for COVID-19. The primary reason people die from COVID-19 is due […]

CODX up 2000% and looking to pioneer COVID-19 testing.

The biotech world is in a frenzy. Testing kit and vaccine companies are experiencing extreme investor backing. Despite occasional pump and dumps, the explosive share price growth for biotechs is continuing. However, a vaccine is not the answer because time is not on our side. Also, if you look at Ebola, Zika, and Sars2, a […]

Quidel stock to pounce after FDA approves rapid antigen COVID-19 test?

The Food and Drug Administration approved the emergency use of Quidel Corporations (NASDAQ:QDEL) rapid antigen testing for use across the country. In recent weeks, antigen testing for COVID-19 has sparked speculation amongst investors – being marked as one of the biggest opportunities in our current market. This year alone has seen Quidel stock reach all […]

Moderna (MRNA) set to cure COVID-19 – is now the time to invest?

MRNA’s key COVID-19 developments so far US government is willing to fund mRNA-173 through every trial until regulatory approval. Biomedical Advanced Research and Development Authority (BARDA) is ready to give Moderna (NASDAQ: MRNA) $483 million to expedite mRNA-173 through clinical development. Lonza Group, via its agreement with Moderna, is manufacturing mRNA-173 at their US and […]

Gilead prepared to surge after FDA approval of COVID-19 treatment Remdesivir

Trump announced on Friday that the US Food and Drug Administration has cleared the emergency use of Remdesivir as a COVID-19 treatment. Gilead Sciences (NASDAQ:GILD) will play a vital role in producing 1.5 million doses for patients across the US suffering critical complications from COVID-19. The now infamous Remdesivir has made headlines over the past […]

Oil plunges to all-time lows – here are our top 3 money-making strategies.

We know why you are here. You want either want to make money off the oil crisis and/or understand the oil crisis. If you want to get straight into the strategies then scroll past the ‘why did oil drop section’. Why did oil drop to $0 and into the negatives? Essentially, oil plummeted to $0 […]

How long can NASDAQ’s bullish run continue to stun the world?

While global indices have struggled to gain substantial momentum, the tech-heavy NASDAQ continues to stun the world. Last week alone, the index catapulted by more than 6.4% to finish at 8650.14 points. Marking, a 23.8% increase over the last month. It will be interesting to see if the NASDAQ can maintain its fine form for […]

Sydney Airport surges off breaking news – is it too late to invest?

The ground is splitting out from under us. On one side, you have investors claiming the bullish recovery is on. While other investors believe the bears are still out for blood. The market divide might be making it challenging for new investors to make sense of the market. Most new investors are looking to snap […]

How Gilead drove a US rally based on optimism.

The Dow Jones rallied upwards of 700 points on Friday as Gilead’s (NASDAQ:GILD) “Wonder Drug”  has shown promising results according to a Chicago University source. The video of Infectious Disease Professor Kathleen Mullane, goes into some detail over the success of Remdesivir in recent trials with patients reporting fast recoveries from COVID-19. Now if you […]

BREAKING: NASDAQ stock shows “100% survival rate” on new COVID-19 treatment

Pluristem Therapeutics Inc. (NASDAQ: PSTI) has made groundbreaking progress in the treatment for COVID-19 in treating severely ill patients. Pluristem uses PLX stem therapy on patients that have critical complications due to COVID-19. The Israeli based biotech released a statement on Monday : confirming they had been cleared by the FDA to proceed with the […]

Morgan Stanley may restructure Virgin’s tattered wings after the government denies a $1.4 billion bailout.

To say that Virgin Australia (ASX: VAH) is finding it challenging to navigate through the COVID-19 storm would be an understatement. Virgin’s possible entry into voluntary administration showcases how the airline is on the brink of collapse. Voluntary admission may be excessive. However, considering Virgin’s cash runway, mountains of debt, and recent decision to stand […]

Does JNJ’s COVID-19 vaccine and 6.3% dividend boost make them a recession-proof stock?

What do Listerine, baby powder, and band-aids all have in common? All of these household products are part of the pharmaceutical conglomerate Johnson and Johnson (NYSE: JNJ). It appears that the pharmaceutical mammoth is immune to the pandemic. While airlines, cruise ships, and travel agents are being hammered, JNJ is almost at a full V […]

WORX makes breakthrough deal on COVID-19 testing – is it too late to invest?

SCworx Corp (WORX: NASDAQ) had a historical day yesterday opening from $2.25 and catapulting itself to highs of $14.00 before closing the ride at $12.02. It is remarkably rare to see gains at this level over one day. The sublime increase came after Scworx Corp announced they had received a purchase “provision” for 48 million […]

If Mesoblast develops a COVID-19 vaccine, could they become the next CSL?

The world needs a vaccine. Because people want their quality of life to return to normal. People do not want to continue entertaining the idea of COVID-19 taking away their loved ones. Our demand for a cure is sparking a drug development frenzy in the biotech sphere. A tsunami of biotechs are now in the […]

How to profit off smart investments during COVID-19?

We are currently living in a time period of upmost significance, a historical event that will forever change humanity. COVID-19 has already taken so much from our global communities. So in response, we want to give our readers a complete guide that will give you the insight and tools needed to develop your own investment strategy. Market […]